Cyanotech Corp (CYAND) — SEC Filings
Cyanotech Corp (CYAND) — 22 SEC filings. Latest: 10-Q (Nov 10, 2025). Includes 7 8-K, 6 10-Q, 5 SC 13D/A.
View Cyanotech Corp on SEC EDGAR
Overview
Cyanotech Corp (CYAND) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 10, 2025: CYANOTECH CORP (CYAND) reported a significant turnaround in net income for the three months ended September 30, 2025, achieving a net income of $1,000 compared to a net loss of $1,150,000 in the prior year period. This improvement was driven by a 19.3% increase in net sales, reaching $6,976,000 from
Sentiment Summary
Across 22 filings, the sentiment breakdown is: 1 bullish, 4 bearish, 16 neutral, 1 mixed. The dominant filing sentiment for Cyanotech Corp is neutral.
Filing Type Overview
Cyanotech Corp (CYAND) has filed 6 10-Q, 7 8-K, 2 DEF 14A, 2 10-K, 5 SC 13D/A with the SEC between Feb 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (22)
Risk Profile
Risk Assessment: Of CYAND's 21 recent filings, 4 were flagged as high-risk, 12 as medium-risk, and 5 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $6,976,000 |
| Net Income | $1,000 |
| EPS | $0.00 |
| Debt-to-Equity | 1.98 |
| Cash Position | $649,000 |
| Operating Margin | 2.7% |
| Total Assets | $24,027,000 |
| Total Debt | $15,962,000 |
Key Executives
- Dr. Gerald R. Cysewski
- Gerald R. Cysewski
- Matthew K. Custer
- Felicia Ladin
- Jennifer C. Rogerson
- Michael Davis
- Michael A. Davis
Industry Context
The microalgae industry, where Cyanotech operates, is characterized by niche markets for nutritional supplements (like spirulina and astaxanthin) and potentially for biofuels or other industrial applications. Growth is driven by increasing consumer demand for natural health products and advancements in cultivation technology. However, the industry can be competitive, with companies facing challenges related to production costs, scalability, and regulatory approvals for new applications.
Top Tags
financials (4) · schedule-13d (4) · Net Loss (3) · Medicinal Chemicals (3) · Botanical Products (3) · amendment (3) · material-agreement (2) · financial-obligation (2) · earnings (2) · governance (2)
Executive Compensation
From the most recent DEF 14A filing (Jul 10, 2025):
- Gerald R. Cysewski — PEO
- Matthew K. Custer — PEO
- Felicia Ladin — Non-PEO Executive
- Jennifer C. Rogerson — Non-PEO Executive
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Income | $1,000 | for the three months ended September 30, 2025, a significant improvement from a $1,150,000 net loss in the prior year. |
| Net Sales | $6,976,000 | for the three months ended September 30, 2025, up 19.3% from $5,845,000 in the prior year. |
| Net Loss | $925,000 | for the six months ended September 30, 2025, an improvement from a $2,352,000 net loss in the prior year. |
| Working Capital | $39,000 | as of September 30, 2025, a decrease from $302,000 as of March 31, 2025, indicating reduced liquidity. |
| Related-Party Line of Credit | $4,200,000 | outstanding as of September 30, 2025, an increase from $3,000,000 as of March 31, 2025, showing increased reliance on related-party financing. |
| Common Shares Outstanding | 7,392,243 | as of November 1, 2025, indicating potential dilution from prior periods. |
| Cash | $649,000 | as of September 30, 2025, an increase from $257,000 as of March 31, 2025, but still a low amount for operations. |
| Long-term Debt to Bank | $2,809,000 | outstanding as of September 30, 2025, with covenant violations noted. |
| SEC File Number | 000-14602 | Identifies the company's filing history with the SEC. |
| IRS Employer Identification Number | 91-1206026 | Unique identifier for tax purposes. |
| Common Stock Shares Outstanding | 10M | Remained constant, suggesting no dilution or buybacks in the quarter. |
| First Foundation Bank Revolving Credit Facility Balance | $203K | Indicates ongoing reliance on external financing for operations. |
| Related Party Revolving Credit Facility Balance | $0 | Suggests no current draw on this facility as of June 30, 2025. |
| Term Loan Maturity Year | 2032 | Provides a long-term debt obligation for the company. |
| Fiscal Year End | 2025-03-31 | The most recent fiscal year for which executive compensation is detailed. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Cyanotech Corp (CYAND)?
Cyanotech Corp has 22 recent SEC filings from Feb 2024 to Nov 2025, including 7 8-K, 6 10-Q, 5 SC 13D/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CYAND filings?
Across 22 filings, the sentiment breakdown is: 1 bullish, 4 bearish, 16 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Cyanotech Corp SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Cyanotech Corp (CYAND) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Cyanotech Corp?
Key financial highlights from Cyanotech Corp's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for CYAND?
The investment thesis for CYAND includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Cyanotech Corp?
Key executives identified across Cyanotech Corp's filings include Dr. Gerald R. Cysewski, Gerald R. Cysewski, Matthew K. Custer, Felicia Ladin, Jennifer C. Rogerson and 2 others.
What are the main risk factors for Cyanotech Corp stock?
Of CYAND's 21 assessed filings, 4 were flagged high-risk, 12 medium-risk, and 5 low-risk.
What are recent predictions and forward guidance from Cyanotech Corp?
Forward guidance and predictions for Cyanotech Corp are extracted from SEC filings as they are enriched.